UCB

Stocks

Market Closed - Euronext Bruxelles 11:55:00 2026-10-08 am EDT			After hours 03:59:59 pm
201.80 ^EUR	-0.98%		202.65	+0.42%

10:36pm	UCB SA - Special Call
Sep. 30	Merck's experimental skin disease drug succeeds in mid-stage study	RE

Published on 10/07/2026 at 10:36 pm EDT - Modified on 10/08/2026 at 02:38 am EDT

S&P Capital IQ

Presenter Speech
Yvonne Naughton (Executives)

Hello, everyone, and welcome to UCB's EADV Capital Markets Call for Institutional Investors and Analysts. My name is Yvonne Naughton, and I lead the

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10:36pm	UCB SA - Special Call
Sep. 30	Merck's experimental skin disease drug succeeds in mid-stage study	RE
Sep. 29	UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session	CI
Sep. 24	BofA Reaffirms UCB at Buy Amid 'Very Confident' Outlook for Psoriasis Drug	MT
Sep. 24	BofA Securities Keeps UCB at Buy	MT
Sep. 23	UCB SA Presents at J.P. Morgan CEO Call Series, Sep-23-2026 08:45 PM
Sep. 23	UCB SA Presents at Bank of America Global Healthcare Conference 2026, Sep-23-2026 10:45 AM
Sep. 11	AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up	MT
Sep. 10	UCB: A rare window of affordability
Sep. 09	UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA (Certolizumab Pegol) In Pregnant Women With Antiphospholipid Syndrome	CI
Sep. 09	UCB wins 'breakthrough therapy' designation for a product
Sep. 01	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
Sep. 01	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies	MT
Aug. 31	Trump announces new round of drug-pricing deals	RE
Aug. 31	Ucb Sa Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing	CI